((自动化翻译由路透提供，请见免责声明 ))
10月28日 - ** EyePoint Pharmaceuticals 股价上涨36.5%，达到12.96美元的五个月新高
** 该公司称其药物Duravyu在糖尿病黄斑水肿的中期试验中显示，患者看清远处物体的能力有所改善$(DME.AU)$
** 糖尿病黄斑水肿是一种导致糖尿病患者视力模糊的眼部疾病。
** 该公司预计将于 2025 年第一季度发布全面业绩报告
** 包括本交易日的走势在内，EYPT股价今年累计下跌了50.8%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.